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Abstract
Introduction: The objectives of this study are to address if and how albumin can be used as an indication of malnutrition in
HIV infected and uninfected Africans.
Methods: In 2005, 710 HIV-infected and 226 HIV-uninfected women enrolled in a cohort study. Clinical/demographic
parameters, CD4 count, albumin, liver transaminases; anthropometric measurements and Bioelectrical Impedance Analysis
(BIA) were performed. Malnutrition outcomes were defined as body mass index (BMI), Fat-free mass index (FFMI) and Fat
mass index (FMI). Separate linear predictive models including albumin were fit to these outcomes in HIV negative and HIV
positive women by CD4 strata (CD4.350,200–350 and ,200 cells/ml).
Results: In unadjusted models for each outcome in HIV-negative and HIV positive women with CD4.350 cells/ml, serum
albumin was not significantly associated with BMI, FFMI or FMI. Albumin was significantly associated with all three
outcomes (p,0.05) in HIV+ women with CD4 200–350 cells/ml, and highly significant in HIV+ women with CD4,200 cells/ml
(P,0.001). In multivariable linear regression, albumin remained associated with FFMI in women with CD4 count,200 cells/
ml( p ,0.01) but not in HIV+ women with CD4.200.
Discussion: While serum albumin is widely used to indicate nutritional status it did not consistently predict malnutrition
outcomes in HIV- women or HIV+ women with higher CD4. This result suggests that albumin may measure end stage
disease as well as malnutrition and should not be used as a proxy for nutritional status without further study of its
association with validated measures.
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Introduction
Sub-Saharan Africa is by far the region most-affected by the
AIDS epidemic [1]. The region has just over 10% of the world’s
population, but is home to 68% of all people living with HIV [1].
HIV infection has adverse consequences on economic develop-
ment and well being including household food insecurity [2]. In
Rwanda HIV prevalence is approximately 3% and is higher in
women than in men (3.6 vs 2.3% respectively) [3]. As in all of sub-
Saharan Africa, HIV infection in Rwanda has adverse conse-
quences on economic development and well being including
household food insecurity. This situation is aggravated by poverty,
which affects 60% of Rwandans, and a high prevalence (.30%) of
malnutrition regardless of HIV status [3].
Africans with advanced HIV disease may also experience
wasting and loss of fat-free mass secondary to several factors. Oral
and gastrointestinal infections associated with HIV can make food
difficult to ingest; other manifestations of advanced HIV disease
can also interfere with an individual’s ability to ingest nutrients.
Additionally, elevated proinflammatory cytokines in untreated
HIV infection, including interleukin-1, interleukin-6, and tumor
necrosis factor a [4,5] can cause anorexia or may promote
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35079catabolism causing weight loss despite sufficient intake of energy
and protein [4,6].
Considering the combined burden of malnutrition in sub
Saharan Africa, and the catabolic condition found in HIV positive
patients, it is important to be able to measure malnutrition in order
to determine if malnutrition is associated with adverse outcomes in
HIV infected Africans. To that end, body composition is an
important measure of nutritional status. The tool most commonly
used to assess adult malnutrition is weight adjusted for height,
expressed as ‘‘body mass index’’ (BMI): weight in kilograms
divided by the square of height measured in meters. The World
Health Organization classifies a BMI,18.5 as a sign of
malnutrition [7]. However BMI can be insensitive to changes in
lean muscle mass (LMM), which is a more accurate marker of
recent change in nutritional status [8]. In women, who represent
.60% of the African HIV infected population, LMM is lower and
proportion of total body fat is higher than in men.
Bioelectrical impedance analysis (BIA) measures body compo-
sition, in particular, fat free mass, which enables estimation of
LMM. BIA is a good tool for assessing body cell mass loss in HIV
positive patients and compares favorably with gold standard
methods, for example dual energy x-ray absorptiometry,
(DXA)(r=0.9) [9,10]. Because of the limitations in expressing
body composition data as kilograms (eg, kg of fat-free mass or fat
mass), similar to BMI it has been suggested to use height(ht)
normalized indices: the fat mass index (FMI, kg of fat mass/ht-m
2)
and the fat-free mass index (FFMI, kg of fat-free mass/ht-m
2)a s
indicators of nutritional status in patients [11,12].
Laboratory parameters may provide an alternate way to
measure malnutrition which may reflect a more immediate state
of malnutrition than mass indices which have built up over time.
History, physical examination, and anthropometric measurements
are essential parts of nutritional evaluation [13]. However, these
tools can be highly subjective and rely on the knowledge and
experience of the evaluator. Incorporating biochemical measure-
ments into routine nutritional assessment provides an often-needed
objective dimension. Serum albumin, which is routinely measured
in developed countries and available in most inpatient and many
ambulatory settings in Africa, is the most used laboratory
parameter for nutritional assessment with low serum albumin
indicating malnutrition [14,15]. However, its ability to discrimi-
nate fully between patients with normal and abnormal nutritional
status is not yet well studied. Low serum albumin has also been
found to occur with a variety of acute and chronic diseases and
thus is associated with higher mortality in a number of different
populations in pathways that may not solely result from
malnutrition. For this reason serum albumin is also often used as
a prognostic indicator of disease progression [16,17]. Several
studies have indicated that lower concentrations of serum albumin,
even within the ‘‘normal’’ range, in HIV infected persons are
associated with more rapid progression to AIDS and all-cause
mortality, independent of other prognostic indicators and
treatments including CD4 cell count, HIV-1 viral load, and
highly active antiretroviral therapy (HAART) [18,19].
An important question in treating HIV-infection in Africa is the
effect of comorbid malnutrition on response to HAART [20]. To
this end it may be important to know if albumin can be used as an
immediate indication of malnutrition, in both research and clinical
settings. Despite the use of serum albumin level as a standard
indicator of nutritional status, its sensitivity and specificity for
malnutrition are not well established in HIV-infected individuals
where low serum albumin often results (independently of
malnutrition) from advanced HIV infection. The present cross-
sectional study uses data collected at entry into a cohort study
conducted in Kigali, Rwanda, to assess the association of serum
albumin with other markers of nutritional status and whether
serum albumin can be used for nutritional assessment among
antiretroviral naı ¨ve HIV infected and HIV uninfected patients.
Materials and Methods
Study population
The Rwandan Women’s Interassociation Study and Assessment
(RWISA) is an observational cohort study designed to assess the
effectiveness and toxicity of antiretroviral therapy in HIV-infected
Rwandan women. Written informed consent was obtained in
accordance with protocols approved by the Rwandan National
Ethics Committee and the Institutional
Review Board of Montefiore Medical Center, Bronx NY, USA.
In 2005, 710 HIV-infected and 226 HIV-uninfected women
enrolled with follow-up visits occurring every six months.
Participants were recruited through grassroots women’s organiza-
tions and clinical care sites for HIV-infected patients. Inclusion
criteria were: age at least 25 years at study entry, willingness to
give informed consent, and no history of receiving antiretroviral
treatment except for possibly single dose nevirapine to prevent
mother-to-child transmission of HIV.
Anthropometrics and body composition measurements
Anthropometric measurements (height and weight, skin-fold
thickness, body circumference at the waist, hip, and chest) and
Bioelectrical Impedance Analysis (BIA) were performed. BIA is a
simple, noninvasive technique that has been recommended for
nutritional assessment studies in the clinical setting [21] and has
been shown to be sufficiently precise for clinical investigation of
body composition analysis [21,22].These evaluations were under-
taken by nurses trained in proper anthropometry with anatomic
placement of the tape measure and location of skin folds by clinical
trainers. Anthropometric measurements were made in duplicate
and in the case of discrepancy a third measurement was done.
Standing height and weight were measured while the participant
was wearing light clothing and no shoes. Two measurements of
skin folds at mid triceps, front thigh, subscapular, and suprailiac
were taken and read to the nearest 0.2 mm, and an average
obtained for each site. Impedance measurements were taken in
duplicate using a standard tetrapolar electrode placement on the
hand and foot. Total body fat and fat-free mass (FFM) were
calculated from BIA measurements using gender-specific equa-
tions that were previously cross-validated in a sample of patients
(white, black, and Hispanic) with and without HIV infection [23]
and have been applied elsewhere in African studies [24,25]
Body mass index was calculated as weight(kg)/(height
2(m). The
Fat Free Mass Index (FFMI) was obtained by dividing calculated
fat-free mass by height-squared. Fat Mass Index (FMI) was
calculated by BMI minus FFMI. In some participants with very
low BMI (,17.0) the calculated FFM was greater than the weight;
in these cases the FFM was set to equal the weight and FMI to
zero. Sum of skin folds variable was generated by adding together
thigh, triceps, and subscapular skin folds.
Patient history and clinical parameters
At study entry, participants were interviewed and a physical
examination was conducted. Income was reported as Rwandan
francs (RWF) monthly, and is shown in RWF and US dollars.
Stage IV HIV disease WHO illness was determined from
participant self-report of extrapulmonary tuberculosis, HIV
wasting syndrome, pneumocystis pneumonia, recurrent severe
pneumonia, Kaposi’s sarcoma, chronic herpes simplex infection of
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encephalopathy, extra pulmonary cryptococcosis, lymphoma, and
invasive cervical carcinoma.
Laboratory data
Whole blood (3.5 mL) was collected in serum separator gel
tubes and centrifuged at 3500 rpm for 10 minutes, and serum was
separated and processed for albumin, aspartate amino transferase
(AST) and alanine amino transferase (ALT) using standard
methods. Abnormal liver function testing was defined as an AST
and/or an ALT value.35 mg/dl, the upper limit of normal in the
testing laboratory. CD4 counts were determined with a FACS
counter (Becton and Dickinson, Immunocytometry Systems, San
Jose, CA, USA). Diagnosis of HIV infection was determined by
having a positive result for HIV-1 antibodies ELISA kits (HIV
Vironostika, Netherlands, and Murex HIV-1.2, Oxford, UK)
which was confirmed by a positive result again with the same test.
Statistical analysis
Separate analyses were done for participants with and without
HIV infection. Further analyses were done for HIV positive
participants by CD4 strata (.350,200–350 and ,200 cell/ml).
Descriptive statistics; (i.e mean, standard deviation), were used to
present continuous variables, and number and percentages for
categorical variables. Analysis of variance test for differences
among continuous variables while Chi-square tests did so for
categorical variables. Linear regression analyses assessed the
relationships between the outcome variables (FMI and FFMI)
and each independent variable. Stepwise selection regression was
used to build multivariate models and a p-value of 0.10 was
necessary to enter the model (p-values less than 0.05 were
considered as statistically significant for other analyses). Potential
confounding was examined by comparing coefficients of the same
variables in univariate to those in multivariate models. Analyses
were conducted using STATA 11.1 (StataCorp LP, College
Station, TX, 2010).
Results
Demographic, clinical and laboratory parameters of study
participants are summarized in Table 1 by HIV/CD4 group
(HIV2, HIV+-CD4.350, HIV+-200#CD4#350, HIV+-
CD4,200). The HIV-negative women were older (P,0.001, for
comparing all HIV/CD4 groups), more likely to be widowed, and
less likely to live with a partner (p=0.003,), and on average had
larger family size (p,0.001). All clinical parameters (pulmonary
tuberculosis, wasting and diarrhea in past 6 months) were
significantly elevated in HIV positive women particularly those
in lower CD4 strata (p,0.001 for all). Among the HIV positive
women only, those with lower CD4 counts were more likely to
report a prior stage IV WHO AIDS-defining condition (p,0.001).
There was no significant difference by HIV/CD4 group in
literacy, income, or having electricity in the home.
While there was no significant difference in mean BMI or Fat
Mass Index in the four HIV/CD4 groups (p=0.09 and p=0.3
respectively), there was a statistically significant difference in mean
FFMI among the four groups: FFMI (kg/m
2) was (mean standard-
deviation) 17.461.5 in HIV negative and 17.561.5, 17.461.6,
17.061.5 in HIV positive women with CD4.350, 200–350 and
CD4,200 cells/ml respectively (p=0.01). Mean serum albumin
(g/dl) systematically dropped from 3.960.5 in HIV negative to
3.660.6, 3.460.6 and 3.360.6 g/dl in HIV positive with CD4
count.350, 200–350 and ,200 cells/ ml respectively (p,0.001).
Among HIV negative women, 5.7% had abnormal AST or ALT
(.35 mg/dl), which was systematically higher with HIV infection
and lower CD4, at 7.4%, 8.1% and 11.8% of HIV positive with
CD4 count,350, 200–350, and ,200 cells/ml respectively, a
difference that was not statistically significant by a standard chi-
square test, but using a trend test obtained P=0.024 (data not
shown).
Univariate analyses of the associations of albumin and
demographic, clinical and other laboratory variables with BMI,
FMI and FFMI are presented in Table 2 stratified by HIV/CD4
group (HIV2, HIV+-CD4.350, HIV+-200#CD4#350, HIV+-
CD4,200). Among demographic parameters, higher income
(.10,000 compared to ,10,000 Rwandan francs monthly was
associated with higher BMI and Fat Mass Index in HIV negative
women and in HIV positive with CD4.350, but not in the HIV+
women with CD4,350 cells/ml. Having electricity in their homes,
a measure of ‘‘disposable’’ income, was highly associated with
higher BMI and FMI among HIV negative women and in HIV
positive groups with CD4.200. In HIV-negative and HIV
positive women with CD4 count.350 cells/ml, serum albumin
was not significantly associated with BMI, FFMI or FMI.
However, In HIV+ women with CD4 count 200–350 cells/ml,
higher albumin was significantly associated with higher BMI
(1.027 kg/m
2 per g/dl of albumin), FFMI (0.404 kg/m
2 per g/dl
of albumin) and FMI (0.655 kg/m
2 per g/dl of albumin)
(p=0.006, p=0.01, p=0.04 respectively). These associations
were even stronger in women with CD4 count,200 cells/ml:
BMI (1.70 kg/m
2 per g/dl increase in albumin), FFMI (0.73 kg/
m
2 per g/dl increase in albumin) and FMI (1.01 kg/m
2 per g/dl
increase in albumin) (P,0.001 for BMI and FFMI and 0.003 for
FMI). Higher hemoglobin was highly associated with higher values
for BMI, FFMI and FMI in HIV positive women with CD4,200
cells/ml( P ,0.001).
We assessed albumin’s independent association with BMI, FMI
and FFMI by forward stepwise selection in multivariable linear
regression models which adjusted for severity of HIV and other
diseases. The only significant independent associations of serum
albumin in these models was with FFMI in HIV+ women with
CD4 counts 200–350 and ,200 cells/ml: estimates 0.44 and
0.37 kg/m
2 per g/dl of albumin, respectively, p=0.03 for both.
Albumin was not independently associated with FFMI in HIV
negative women or HIV+ women with CD4.350 cells/ml (table 3).
There was also no significant independent association of serum
albumin with FMI in any of the groups (Table 4). In fact, albumin
did not have a strong enough association to enter any models for
FMI. However hemoglobin was independently associated with
both FFMI (estimate in kg/m
2 per mg/dl of hemoglobin, p-value)
(0.19, p=0.007) and FMI (0.4, p,0.02) in women with CD4,200
cells/ml.
Discussion
Serum albumin level is commonly used as a nutritional marker
in many clinical settings [14,15,26] because of its ease of
measurement and its inclusion in many chemistry profiles.
However, our study found that serum albumin did not predict
other measures of nutritional status (BMI, FFMI or FMI) in either
HIV-negative or positive African women, with the exception of
one small subgroup. The only significant associations of serum
albumin with the body composition indices we measured was with
FFMI in HIV+ women with very advanced disease
(CD4,200cells/ml), suggesting that the lower serum albumin
level was a marker of the catabolic state of later-stage disease,
rather than of poor nutritional status. For example, in patients
found to be severely malnourished on clinical examination with
Serum Albumin and Nutritional Status
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negative and 3.1 g/dl in HIV positive women (data not shown).
Thus, despite their low BMI, the HIV negative women tended to
have serum albumin levels in the normal range of 3.4 to 5.4 g/dl
whereas in HIV positive women with BMI,18.5 kg/m
2 the mean
serum albumin level was well below the lower limit of this range.
This suggests a specific effect of advanced HIV disease in lowering
BMI and serum albumin rather than a direct association of low
serum albumin with low BMI.
Albumin levels are influenced by many clinical manifestations
other than nutritional status [14] , which may limit the utility of
using serum albumin as a specific marker of malnutrition. For
example, illnesses that increase albumin loss, such as nephrotic
syndrome, or diseases that decrease albumin synthesis, such as
cirrhosis, will result in lower albumin levels regardless of
nutritional status [27]. To that end, we found that lower values
of serum albumin correlate with lower CD4 cell count. The mean
serum albumin systematically dropped from 3.960.5 g/dl in HIV
negative to 3.660.6, 3.460.6 and 3.360.6 g/dl in HIV positive
participants with CD4 count.350, 200–350 and ,200 cells/ml
respectively. Our findings are similar to the results from a Kenyan
study which indicated that a decrease in albumin of over 10% was
associated with a 3.5-fold increase in the risk of progressing to a
CD4 count,200 cells/ml [28]. Feldman and colleagues in their
study of serum albumin as a predictor of survival in HIV-infected
women in the Women’s Interagency HIV Study, reported that a
Table 1. Baseline characteristics of study participants (n=895).
Participant Characteristics
HIV NEGATIVE
(n=217) HIV POSITIVE (n=678) P-VALUE
a
CD4.350
b
(n=187)
CD4 200–350
b
(n=255)
CD4,200
b
(n=236)
Demographic parameters
Age, years (mean6SD) 42.4610.5 34.266.9 35.266.7 34.967.1 ,0.001
Marriage, n (%)
Legally or living with a partner 77 (37.4%) 80 (43.2%) 94 (36.8%) 70 (30.0%) 0.003
Widowed 104 (50.5%) 68 (36.8%) 109 (42.7%) 103 (44.2%)
Others 25 (12.1%) 37 (20.0%) 52 (20.4%) 60 (25.7%)
Number of people live with you n (%)
None, 0 7 (3.8%) 8 (3.2%) 16 (6.9%) ,0.001
Less than 3 22 (11.1%) 37 (20.1%) 59 (23.3%) 56 (24.2%)
3–5 people 103 (52.0%) 98 (53.3%) 129 (50.9%) 114 (49.3%)
More than 5 73 (36.9%) 42 (22.8%) 57 (22.5%) 45 (19.5%)
Monthly Income, Rwandan Francs (US$)
,10,000(18$) 90 (45.7%) 62 (33.7%) 95 (37.8%) 85 (37.1%) 0.055
10000–35000 (18–60$) 74 (37.6%) 101 (54.9%) 122 (48.6%) 109 (47.6%)
.35 000 (.60$) 33 (16.7%) 21 (11.4%) 34 (13.5%) 35 (15.3%)
Are Literate, n(%) 144 (69.9%) 141 (76.2%) 198 (77.9%) 177 (76.6%) 0.21
Have Electricity in house n(%) 21 (10.7%) 23 (12.50%) 36 (14.3%) 20 (8.7%) 0.26
Clinical parameters
Diarrhea in past 6 months n(%) 17 (8.1%) 27 (14.6%) 56 (22.1%) 78 (33.5%) ,0.001
Pulmonary tuberculosis n(%) 4(1.9%) 19 (10.3%) 27 (10.6%) 41 (17.6%) ,0.001
Wasting n(%) 1 (0.5%) 12 (6.5%) 19 (7.5%) 33 (14.2%) ,0.001
WHO Class 4 n(%) NA 45 (24.1%) 79 (30.9%) 89 (37.7%) ,0.001
Anthropometric measurements
Body Mass Index ,kg/m
2 21.363.8 21.963.9 21.963.9 21.163.7 0.09
Fat mass Index, kg/m
2 3.963.1 4.163.1 4.563.3 4.163.2 0.30
Fat free mass Index, kg/m
2 17.461.5 17.561.5 17.461.6 17.061.5 0.01
Sum of skin folds ,mm (Thigh, Triceps, Subscapular) 55620 51.1619.7 53.9620.2 50.2616.7 0.07
Laboratory parameters
CD4, cells/ ml, (mean6SD) NA 49761.4 27260.4 12560.5 ,0.001
Albumin g/dl, (mean6SD) 3.960.5 3.660.6 3.460.6 3.360.6 ,0.001
Hemoglobin mg/dl (mean6SD) 14.361.4 13.561.2 13.161.7 12.761.7 ,0.001
Abnormal Liver tests
c, n(%) 12 (5.7%) 13 (7.4%) 19 (8.1%) 26 (11.8%) 0.13
aP-value is for comparing all four HIV/CD4 groups.
bn(%) for categorical variables or mean6standard-deviation for continuous variables.
cAlanine aminotransferase or aspartate aminotransferase.35 mg/dL.
doi:10.1371/journal.pone.0035079.t001
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35079single measurement of albumin at baseline was very prognostic of
survival in patients with CD4 cell counts of ,200 cells/ml, with the
hazard of death increasing 8-fold in those with albumin ,35 mg/
L compared with those with albumin .45 mg/l [19].
Prior studies of US patients have reported that even early-stage
of HIV infection results in considerable loss of body weight and
changes in body fat distribution [29]. In contrast to these studies,
we found that among ART naı ¨ve HIV-infected Rwandan women
the BMI, body fat index, and fat-free mass index (among those
with CD4.200 cells/ml), were similar to those found in HIV-
uninfected women (table 1). Our findings are supported by a prior
study conducted in South Africa assessing body composition of
South African lactating women in relation to HIV serostatus
which demonstrated no significant difference in mean BMI (24.6
and 25.3 kg/m
2 with a p-value of 0.3) in HIV-infected and
uninfected women, respectively [30].
In this study, we did not use a gold standard measurement of
body composition, such as the dual-energy x-ray absorptiometry.
Furthermore, the BIA prediction method used has not yet been
validated in the Rwandan population. As a result, our estimates of
Table 3. Final stepwise multivariate linear regression models for the association of serum Albumin and other selected
characteristics with FAT FREE MASS INDEX (FFMI) among HIV-negative women and HIV Positive by CD4 strata
1.
Participant Characteristics HIV POSITIVE
HIV NEGATIVE CD4.350 CD4 200–350 CD4,200
estimate(95%CI) kg/m
2 estimate(95%CI) kg/m
2 estimate(95%CI) kg/m
2 estimate(95%CI) kg/m
2
Electricity (Yes vs. No) 0.48(20.19, 1.63)
Pulmonary tuberculosis (Yes vs.
No)
20.59(22.1, 0.8)
Marital status 20.53*(21.1, 20.01)
Widowed vs. Married/Living
with Partner
20.40(20.04, 0.2)
Other vs. Married/Living with
Partner
Literate (Yes vs. No) 0.44(20.06, 0.9) 0.53*(0.05, 1.01)
Diarrhea (Yes vs. No) 20.55*(21.05, 20.05)
WHO stage IV 20.22*(0.7, 0.2)
CD4 count (per 100 cells) 0.41(20.07, 0.9)
Albumin (g/dl) 0.35*(0.04, 0.7) 0.41*(0.04, 0.7)
Hemoglobin (mg/dl) 0.19**(0.05, 0.3)
1Numbers are kg/m
2 changes in Fat Mass Index per unit increase in row covariate given all other variables in model are unchanged.
Asterisks represent p-values for association within the column HIV/CD4 group (*,0.05, **,0.01, ***,0.001).
doi:10.1371/journal.pone.0035079.t003
Table 4. Final stepwise multivariate linear regression models for the association of serum albumin and other selected
characteristics with FAT MASS INDEX (FMI) among HIV-negative women and HIV Positive by CD4 strata
1.
Participant Characteristics HIV POSITIVE
HIV NEGATIVE CD4.350 CD4 200–350 CD4,200
estimate(95%CI) kg/m
2 estimate(95%CI) kg/m
2 estimate(95%CI) kg/m
2 estimate(95%CI) kg/m
2
Electricity (Yes vs. No) 2.19**(0.7, 3.6) 2.38**(26.9, 3.8)
Monthly Income, Rwandan
Francs
10000–35000 vs. ,10000 1.08*(0.1, 2.1) 0.86(20.1, 1.8)
.35000 vs. ,10000 1.65**(0.3, 2.9) 1.57*(0.2, 2.9)
Marital status
Widowed vs. Married/Living
with Partner
20.05(21.0, 0.9)
Other vs. Married/Living with
Partner
1.27(20.2, 2.7 )
Hemoglobin (mg/dl) 0.40*(0.002, 0.8) 0.40**(0.14, 0.6)
WHO stage IV 20.70(21.7, 0.26)
1Numbers are kg/m
2 changes in Fat Mass Index per unit increase in row covariate given all other variables in model are unchanged.
Asterisks represent p-values for association within the column HIV/CD4 group (*,0.05, **,0.01, ***,0.001).
doi:10.1371/journal.pone.0035079.t004
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35079body composition may not be accurate because of variations
across ethnic groups [21]; this would make it harder to detect any
associations that existed between albumin and the different body
composition components. However, we believe any such effect
would be small as we have used gender specific equations that
were previously cross validated in individuals of different race
groups (white, black, and Hispanic) among men and women, who
were both healthy controls and HIV-infected patients [23].
Moreover, the equations have been used widely in other studies
from Africa with meaningful findings [24,25,31]. Our study is also
limited in determination of direction of causality by its cross-
sectional design and in generalizability to men as the study
population consisting of only women. However, as 60% of HIV-
infected Africans are women [32] and body composition is
different in women compared to men, it is important to assess
metabolic parameters in African women specifically.
In summary, we have found that malnutrition, defined by the
WHO standard of low BMI, is common in Rwandan women,
independent of HIV status, but that no measure of nutritional
status in our cohort was systematically associated with serum
albumin. Our study suggests that albumin should not be used as a
proxy for nutritional status in HIV infected Rwandan women and
probably in other individuals with advanced disease in both
developing and developed countries. Further studies of association
of serum albumin with validated measures of nutritional status are
needed in diverse populations. Other specific markers such as
transthyretin (also known as pre-albumin) that have shown to be
sensitive in assessing nutritional status [33] should also be validated
in a similar fashion.
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